Amylin Gets Approvable Letter Despite Recommendation.(Symlin conditionally approved)(Brief Article)(Statistical Data Included)

The FDA issued Amylin an "approvable" letter for Symlin, the company's lead drug candidate for both Type I and insulin-dependent Type II diabetes patients.

The FDA called for additional tests before it will clear Symlin for marketing. Symlin is an analogue of human amylin, a hormone secreted with insulin by the beta cells in the pancreas. Amylin proposes injecting diabetes patients with Symlin three times a day in conjunction with insulin. The product controls blood sugar and helps reduce weight gain.

Amylin's stock closed Oct. 12 at $8.59. up $1.27, or 17.4 percent.

In addition to the news on Symlin, Amylin released a statement saying it plans to enter …